Focus on COPD
CTC-Actiwise™ is CTC’s tool for monitoring and follow up of COPD patients.
COPD (Chronic Obstructive Pulmonary Disease) affects 5 – 7 % of the population in most industrialized countries. The disease is strongly related to smoking with a 20 to 30 years time lap. Due to slow and gradual development only 40 % of people suffering from COPD are believed to be in contact with health care. Still, according to WHO the disease is the third most important cause of death. In Sweden COPD account for approximately 1 % of total health care spending.
The strategy to improve health outcome for COPD patients involves two major steps, smoke cessation and prevention and secondly to improve health related quality of life, and especially to decrease the risk of getting severe exacerbation.
Traditionally, the diagnosis and staging of the disease has been relying on lung function parameters such as FVC (Forced Expiratory Volume) and FEV1 (Forced Expiratory Volume in 1 second). Indeed there is a ruff association between the grade of obstruction and risk for exacerbations and decreased life expectancy. However, on a personal level, lung function alone is a very poor predictor. Despite the drawbacks from commonly used lung function tests, In the short term perspective, the effect on FEV and FVC have been commonly used as primary parameters in clinical trials.
In a long term perspective, exacerbations and mortality Lung are commonly used. While the latter are reliable outcomes, these kinds of studies are both expensive and time consuming. Usually, a large number of subjects need to be included in order to reach sufficient poser, and the time required is usually up to one year. Thus there is need for parameters that may be used in short term studies on less number of patients. These parameters should have a strong predictive value.
Presently CTC is working with a Swedish research group at the Lung Clinic of the prestigious Lund University Hospital, and also with a major supplier of drugs in the COPD area. Hypotheses regarding possible biomedical predicators have been set up and are now being tested. A full-scale commercial system is to be developed gradually.
Long term the intention is to make way for better understanding of the mental, medical and physical status of the COPD patient and thus open up for better diagnoses and treatment. Short term the aim is for increasing cost efficiency and cost reductions by fewer exacerbations and less frequent calls for costly emergency services. Studies indicate a possibility for > 17 % reduction of emergency calls.